EYPT
Price
$6.16
Change
-$0.19 (-2.99%)
Updated
Feb 21, 04:59 PM (EDT)
Capitalization
420.43M
6 days until earnings call
GLYC
Price
$0.30
Change
-$0.00 (-0.00%)
Updated
Feb 21, 04:57 PM (EDT)
Capitalization
19.11M
6 days until earnings call
Ad is loading...

EYPT vs GLYC

Header iconEYPT vs GLYC Comparison
Open Charts EYPT vs GLYCBanner chart's image
EyePoint Pharmaceuticals
Price$6.16
Change-$0.19 (-2.99%)
Volume$15.39K
Capitalization420.43M
GlycoMimetics
Price$0.30
Change-$0.00 (-0.00%)
Volume$5.41K
Capitalization19.11M
EYPT vs GLYC Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. GLYC commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and GLYC is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (EYPT: $6.35 vs. GLYC: $0.30)
Brand notoriety: EYPT and GLYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 78% vs. GLYC: 118%
Market capitalization -- EYPT: $420.43M vs. GLYC: $19.11M
EYPT [@Biotechnology] is valued at $420.43M. GLYC’s [@Biotechnology] market capitalization is $19.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileGLYC’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • GLYC’s FA Score: 0 green, 5 red.
According to our system of comparison, EYPT is a better buy in the long-term than GLYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 3 TA indicator(s) are bullish while GLYC’s TA Score has 6 bullish TA indicator(s).

  • EYPT’s TA Score: 3 bullish, 5 bearish.
  • GLYC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than EYPT.

Price Growth

EYPT (@Biotechnology) experienced а +0.63% price change this week, while GLYC (@Biotechnology) price change was +6.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

EYPT is expected to report earnings on May 07, 2025.

GLYC is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($420M) has a higher market cap than GLYC($19.1M). GLYC YTD gains are higher at: 21.084 vs. EYPT (-14.765). GLYC has higher annual earnings (EBITDA): -36.73M vs. EYPT (-102.3M). EYPT has more cash in the bank: 254M vs. GLYC (14.4M). GLYC has less debt than EYPT: GLYC (262K) vs EYPT (21.9M). EYPT has higher revenues than GLYC: EYPT (45.7M) vs GLYC (10K).
EYPTGLYCEYPT / GLYC
Capitalization420M19.1M2,199%
EBITDA-102.3M-36.73M279%
Gain YTD-14.76521.084-70%
P/E RatioN/AN/A-
Revenue45.7M10K457,000%
Total Cash254M14.4M1,764%
Total Debt21.9M262K8,359%
FUNDAMENTALS RATINGS
EYPT vs GLYC: Fundamental Ratings
EYPT
GLYC
OUTLOOK RATING
1..100
1033
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9047
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (63) in the Pharmaceuticals Major industry is in the same range as GLYC (87) in the Biotechnology industry. This means that EYPT’s stock grew similarly to GLYC’s over the last 12 months.

EYPT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GLYC (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to GLYC’s over the last 12 months.

EYPT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as GLYC (98) in the Biotechnology industry. This means that EYPT’s stock grew similarly to GLYC’s over the last 12 months.

GLYC's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for EYPT (90) in the Pharmaceuticals Major industry. This means that GLYC’s stock grew somewhat faster than EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for GLYC (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than GLYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTGLYC
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
POSAX8.61N/A
N/A
Principal Global Real Estate Sec A
KTRAX9.12N/A
N/A
DWS Global Income Builder A
ADGYX25.77N/A
N/A
AB Core Opportunities Advisor
EIPDX16.40N/A
N/A
Parametric Dividend Income I
CSJZX67.80N/A
N/A
Cohen & Steers Realty Shares Z

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-1.85%
LYRA - EYPT
58%
Loosely correlated
+0.10%
ATHE - EYPT
54%
Loosely correlated
+5.01%
GLYC - EYPT
47%
Loosely correlated
-3.02%
OCUL - EYPT
46%
Loosely correlated
-1.76%
BEAM - EYPT
41%
Loosely correlated
-2.79%
More

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-3.02%
LYRA - GLYC
76%
Closely correlated
+0.10%
EYPT - GLYC
47%
Loosely correlated
-1.85%
AXON - GLYC
36%
Loosely correlated
-8.70%
IONS - GLYC
35%
Loosely correlated
+2.77%
MDGL - GLYC
34%
Loosely correlated
+2.15%
More